S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in

MeiraGTx Stock Forecast, Price & News

-0.46 (-2.92 %)
(As of 01/21/2021 12:00 AM ET)
Today's Range
Now: $15.28
50-Day Range
MA: $15.39
52-Week Range
Now: $15.28
Volume98,146 shs
Average Volume97,704 shs
Market Capitalization$586.94 million
P/E RatioN/A
Dividend YieldN/A
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is based in New York, New York.
MeiraGTx logo


Overall MarketRank

1.45 out of 5 stars

Medical Sector

485th out of 1,926 stocks

Biological Products, Except Diagnostic Industry

63rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:MGTX



Sales & Book Value

Annual Sales$13.29 million
Book Value$5.22 per share


Net Income$-54,750,000.00
Net Margins-283.20%


Market Cap$586.94 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
-0.46 (-2.92 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

How has MeiraGTx's stock been impacted by COVID-19?

MeiraGTx's stock was trading at $14.10 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MGTX shares have increased by 8.4% and is now trading at $15.28.
View which stocks have been most impacted by COVID-19

Is MeiraGTx a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MeiraGTx stock.
View analyst ratings for MeiraGTx
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MeiraGTx?

Wall Street analysts have given MeiraGTx a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MeiraGTx wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as MeiraGTx's CEO?

1,448 employees have rated MeiraGTx CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among MeiraGTx's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for MeiraGTx

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) announced its quarterly earnings data on Thursday, November, 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.70) by $0.53. The firm had revenue of $5.09 million for the quarter. MeiraGTx had a negative return on equity of 29.14% and a negative net margin of 283.20%.
View MeiraGTx's earnings history

What price target have analysts set for MGTX?

4 brokerages have issued 1-year target prices for MeiraGTx's shares. Their forecasts range from $20.00 to $45.00. On average, they anticipate MeiraGTx's stock price to reach $33.00 in the next year. This suggests a possible upside of 116.0% from the stock's current price.
View analysts' price targets for MeiraGTx
or view Wall Street analyst' top-rated stocks.

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), (KDMN), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the following people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 56, Pay $8.48M)
  • Mr. Richard Brian Giroux B.A., COO & CFO (Age 47, Pay $7.47M)
  • Mr. Robert Wollin J.D., Gen. Counsel & Sec.
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer (Age 58)
  • Prof. Gregory A. Petsko D.Phil., Ph.D., Chief Scientist & Chairman of Scientific Advisory Board
  • Ms. Christine E. Sheehy, Sr. VP of Global Integration
  • Mr. Joel P. Brooks, Sr. VP of Fin. (Age 62)
  • Mr. Tim Randall, Sr. VP of Risk & Internal Controls
  • Dr. Alastair Leighton, Sr. VP of Manufacturing & Supply Chain
  • Dr. Robert K. Zeldin M.D., Chief Medical Officer (Age 58)

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (1.17%). Company insiders that own MeiraGTx stock include Alexandria Forbes, Joel S Marcus, Life Sciences Maste Perceptive, Nicole Seligman, Richard Giroux, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends for MeiraGTx

Which major investors are buying MeiraGTx stock?

MGTX stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive, and Nicole Seligman.
View insider buying and selling activity for MeiraGTx
or or view top insider-buying stocks.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $15.28.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $586.94 million and generates $13.29 million in revenue each year. The company earns $-54,750,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. MeiraGTx employs 206 workers across the globe.

What is MeiraGTx's official website?

The official website for MeiraGTx is www.meiragtx.com.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.